Ianalumab versus placebo for Sjögren's disease with high symptom burden
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older
- You have been diagnosed with Sjögren's disease confirmed by specific blood tests (anti-Ro/SSA antibodies) and clinical criteria
- You have moderate to high symptoms of dry mouth and overall symptom burden (measured over 14 days)
- You have some biological signs of disease activity in blood work (abnormalities linked to Sjögren's, not other conditions)
- You still produce some saliva when your mouth is stimulated (more than 0.3 mL per minute)
- You have not received certain immune-suppressing treatments recently (B-cell-depleting drugs, belimumab, rituximab, or similar medications within specific timeframes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IBI355 for people with moderate-to-severe Sjögren's disease. It aims to reduce inflammation and improve symptoms by targeting part of the immune system.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This trial tests an experimental medication called ONO-4915 for people with primary Sjögren's disease. It aims to see if the drug can reduce dryness and other symptoms.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
Hear when a new Sjögren´s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.